Peter A. Pinto, MD

U.S. National Institutes of Health

Bethesda, MD

Peter A. Pinto, MD, is an Investigator and faculty member in the Urologic Oncology Branch of the National Cancer Institute in Bethesda, Maryland. Following a residency in Urologic Surgery at Long Island Jewish Medical Center - Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute at Johns Hopkins Hospital in Baltimore, Maryland. Dr. Pinto is a board-certified urologic surgeon specializing in oncology and is the Director of the Urologic Oncology Fellowship Program at the National Cancer Institute. He is nationally and internationally recognized as an expert in the minimally invasive treatment of urologic cancers, specializing in laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer.

Disclosures:

Talks by Peter A. Pinto, MD

Should MRI Be Used to Monitor for AS? Pro Argument

Posted by Peter A. Pinto, MD | Jul 2018

Peter A. Pinto, MD, argues that MRI can help select prostate cancer patients for active surveillance (AS). While MRI has some limitations, with proper application, it can reduce patient and urologist anxiety, repeat biopsies, and amount of cores taken during AS. Subsequently, this will reduce morbidity, bleeding, erectile dysfunction, and infections related to biopses.

Peter A. Pinto, MD

U.S. National Institutes of Health

Bethesda, MD

Talks by Peter A. Pinto, MD

Should MRI Be Used to Monitor for AS? Pro Argument

Join the GRU Community

You have Successfully Subscribed!